Earlier this quarter, we announced that partner companies Clarient (Nasdaq: CLRT) and Avid Radiopharmaceuticals had signed definitive agreements to be acquired by GE Healthcare and…
Posted by
For the second time in as many weeks, I am pleased to announce that a major player in the pharmaceutical industry has recognized the value…
Posted by
Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…
Posted by
At Safeguard Scientifics, our strategy is to provide growth capital for entrepreneurial and innovative life sciences and technology companies, build value in those companies and…
Posted by
According to the latest MoneyTree survey conducted by PricewaterhouseCoopers and the National Venture Capital Association, venture capital investing in the third quarter of 2010 was…
Posted by
Today, we were honored by the Philadelphia Business Journal with the Inaugural Life Sciences Venture Impact Award, which “goes to the venture capital firm from…
Posted by
Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…
Posted by
The data from Thomson Reuters/NVCA on venture capital investing over the past 10 years has sparked an onslaught of debate and media coverage highlighting the…
Posted by
On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…
Posted by
